- Home
- ASAN vs IBRX Comparison
ASAN vs IBRX Comparison
Compare ASAN & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASAN
- IBRX
- Stock Information
- Founded
- ASAN 2008
- IBRX 2014
- Country
- ASAN United States
- IBRX United States
- Employees
- ASAN N/A
- IBRX N/A
- Industry
- ASAN Retail: Computer Software & Peripheral Equipment
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ASAN Technology
- IBRX Health Care
- Exchange
- ASAN Nasdaq
- IBRX Nasdaq
- Market Cap
- ASAN 2.7B
- IBRX 2.4B
- IPO Year
- ASAN 2020
- IBRX N/A
- Fundamental
- Price
- ASAN $15.74
- IBRX $5.10
- Analyst Decision
- ASAN Hold
- IBRX Buy
- Analyst Count
- ASAN 17
- IBRX 2
- Target Price
- ASAN $15.19
- IBRX $17.38
- AVG Volume (30 Days)
- ASAN 1.6M
- IBRX 7.2M
- Earning Date
- ASAN 12-05-2024
- IBRX 11-12-2024
- Dividend Yield
- ASAN N/A
- IBRX N/A
- EPS Growth
- ASAN N/A
- IBRX N/A
- EPS
- ASAN N/A
- IBRX N/A
- Revenue
- ASAN $689,298,000.00
- IBRX $7,332,000.00
- Revenue This Year
- ASAN $12.59
- IBRX $1,563.18
- Revenue Next Year
- ASAN $11.75
- IBRX $1,262.20
- P/E Ratio
- ASAN N/A
- IBRX N/A
- Revenue Growth
- ASAN 13.65
- IBRX 1218.71
- 52 Week Low
- ASAN $11.05
- IBRX $3.10
- 52 Week High
- ASAN $23.44
- IBRX $10.53
- Technical
- Relative Strength Index (RSI)
- ASAN 75.63
- IBRX 54.10
- Support Level
- ASAN $13.53
- IBRX $4.80
- Resistance Level
- ASAN $15.24
- IBRX $5.38
- Average True Range (ATR)
- ASAN 0.55
- IBRX 0.49
- MACD
- ASAN 0.12
- IBRX -0.07
- Stochastic Oscillator
- ASAN 97.29
- IBRX 46.21
About ASAN Asana Inc.
Asana is a provider of collaborative work management software delivered via a cloud-based SaaS model. The firm's solution offers scalable, dynamic tools to improve the efficiency of project and process management across countless use cases, including marketing programs, managing IT approvals, and performance management. Asana's offering supports workflow management across teams, provides real time visibility into projects, and reporting and automation capabilities. The firm generates revenue via software subscriptions on a per seat basis.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.